Corient Private Wealth LP Takes $1.28 Million Position in TransMedics Group, Inc. $TMDX

Corient Private Wealth LP bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 19,289 shares of the company’s stock, valued at approximately $1,281,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Silvant Capital Management LLC acquired a new position in TransMedics Group in the second quarter valued at $26,000. Harvest Fund Management Co. Ltd acquired a new position in TransMedics Group during the 3rd quarter valued at about $29,000. North Star Investment Management Corp. bought a new stake in TransMedics Group during the first quarter worth $30,000. Ascentis Independent Advisors purchased a new position in shares of TransMedics Group in the 1st quarter worth approximately $30,000. Finally, Allworth Financial LP grew its position in TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after buying an additional 113 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Up 3.4%

TMDX stock opened at $89.98 on Friday. The company’s 50 day moving average is $80.14 and its 200 day moving average is $92.21. TransMedics Group, Inc. has a 1-year low of $60.10 and a 1-year high of $156.00. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of 23.13 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). The firm had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.92 EPS. Sell-side analysts predict that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on TMDX shares. Piper Sandler restated an “overweight” rating and issued a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Zacks Research cut shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $124.00 price objective on shares of TransMedics Group in a report on Tuesday, June 30th. Finally, Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $124.18.

Insiders Place Their Bets

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This represents a 36.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by insiders.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.